Research ArticleResearchMedication SafetyPatient Education

Periurethral estrogen was noninferior to intravaginal application for recurrent UTI prevention

Obstetrics and Gynecology (PubMed)Jul 27, 2026

AI-summarized from the linked source. Educational brief, not medical advice.

Brief summary

In a randomized noninferiority trial of 114 postmenopausal participants with recurrent urinary tract infection, periurethral estradiol cream produced a similar six-month UTI-free proportion to intravaginal application.

What NurseJet pulled from the source

The single-center TAPER trial compared twice-weekly periurethral application of 0.5 g estradiol cream with intravaginal application of 1.0 g. At six months, 50.9% of the periurethral group and 52.6% of the intravaginal group were UTI-free; the risk difference was -1.75 percentage points with a 95% confidence interval of -20.0 to 17.0. Both groups had lower vaginal pH, and vaginal itching at three months was reported more often with intravaginal use.

Why this matters for nurses

Older adults using vaginal estrogen may need clear teaching about dose, location, schedule, expected effects, and adverse symptoms. The trial offers evidence about an alternate application technique while preserving the need for individualized prescribing and recurrent-UTI evaluation.

Bedside takeaway

Periurethral and intravaginal estradiol application produced similar six-month UTI-free proportions in this trial.

How This Applies in Practice

Use this when: Teaching a postmenopausal patient who has vaginal estrogen prescribed for recurrent UTI prevention.

On your shift

Verify the prescribed product, dose, route, application location, and schedule before teaching the technique.
Use teach-back to confirm application steps and how the patient will track recurrent urinary symptoms and missed doses.
Document irritation, bleeding, recurrent infection symptoms, or difficulty using the applicator and notify the prescriber.

Keep in mind: The study compared specific estradiol cream doses and techniques and does not replace individualized evaluation. Follow facility policy and patient-specific provider orders.

Key takeaways

The nonblinded, single-center trial randomized 114 postmenopausal participants with laboratory-proven recurrent UTI.
At six months, 50.9% of the periurethral group and 52.6% of the intravaginal group were UTI-free.
Periurethral application met the prespecified noninferiority comparison, which used a 25-percentage-point margin.
Participants were predominantly White and had a mean age of 71.1 years, limiting generalizability.

Practice implications

When vaginal estrogen is prescribed for recurrent UTI prevention, teach the ordered application technique using plain language and confirm understanding. Document adherence, recurrent symptoms, irritation, bleeding, or other adverse effects and route concerns to the prescribing clinician.

Limitations & cautions

The trial was single-center and nonblinded, used a relatively wide 25-percentage-point noninferiority margin, enrolled predominantly White participants, and followed outcomes for six months. The abstract does not establish comparative effectiveness beyond the studied doses and techniques.
AI-summarized from the linked source. Review the original article before applying to practice.

Citations

Exact source links

Open source

Public citations are filtered to exact credible source pages. Homepage-only or invalid links stay in admin review and are not shown here.

Obstetrics and Gynecology (PubMed)

Obstetrics and Gynecology (PubMed). Vaginal Estrogen Application Techniques for Prevention of Urinary Tract Infection: A Randomized Trial.

Open original source

https://pubmed.ncbi.nlm.nih.gov/42492951/

Professional education only

This summary does not replace clinical judgment, facility policy, provider orders, or official guidelines. Verify practice changes against the original source and local protocol.

Related briefs

More updates for this clinical area

Back to Discover

Renal failure (PubMed)Sep 7, 2026Research Article

A single-center retrospective cohort found that approximately one quarter of laboratory-defined acute kidney injury cases on internal medicine wards were not documented, particularly when maximal creatinine was lower.

Med-SurgAI summaryReview source

Research ArticleResearchQuality ImprovementAI summary · original source linked below

Among 161 adult hospitalizations meeting serum-creatinine criteria for acute kidney injury, 39 cases (24.2%) were undocumented. Length of stay and in-hospital mortality did not differ significantly by documentation status.

Key takeaways

In the 149 hospitalizations with a demonstrable creatinine change, 33 cases (22.1%) were undocumented.
Higher maximal creatinine was associated with lower adjusted odds of underdocumentation.
The study did not test whether a detection or documentation intervention improves care or outcomes.

Why this matters on shift

A smaller creatinine rise may receive less attention even when it meets the study's laboratory definition of acute kidney injury, which can affect how renal risk is communicated across the inpatient team.

Bedside takeaway

Trend ordered renal-function results and communicate clinically important changes through local escalation and documentation workflows.

Nursing implications

Trend ordered renal-function results and communicate clinically important changes through the care team according to local escalation and documentation workflows.

Limitations & cautions

Abstract-only summary. This was a retrospective, single-center study of 161 hospitalizations; urine-output criteria and reliable preadmission creatinine values were unavailable, and the reference creatinine method may affect case classification.
AI-summarized from the linked source. Review the original article before applying to practice.

Citations · exact source links

Renal failure (PubMed). Underdocumentation of laboratory-defined acute kidney injury in internal medicine wards: a retrospective cohort study.

Open original sourceFull brief

AI-summarized from the linked source. Review the original article before applying to practice.

European heart journal (PubMed)Sep 6, 2026Research Article

In the pragmatic TARGET-D randomized trial, vitamin D dosing titrated to a serum target did not significantly reduce the composite of death, recurrent myocardial infarction, heart-failure hospitalization, or stroke after myocardial infarction.

Telemetry Med-SurgAI summaryReview source

Research ArticleResearchMedication SafetyPatient EducationAI summary · original source linked below

Among 630 participants followed for an average of 4.2 years, major cardiovascular events occurred in 15.7% with targeted vitamin D management and 18.4% with usual care (hazard ratio 0.85, 95% CI 0.58 to 1.24; P=0.40).

Key takeaways

At baseline, 87% of participants had a 25-hydroxyvitamin D level of 40 ng/mL or lower.
The primary composite outcome and the individual outcomes of death, heart-failure hospitalization, and stroke were not significantly different.
A lower recurrent-MI rate was a secondary finding and should not override the nonsignificant primary result.

Why this matters on shift

The trial cautions against presenting targeted vitamin D supplementation as a proven strategy for reducing major cardiovascular events after myocardial infarction.

Bedside takeaway

Present vitamin D as prescribed supplementation, not as a replacement for established post-MI secondary prevention.

Nursing implications

Reinforce the prescribed secondary-prevention plan and avoid implying that vitamin D replaces therapies with established post-MI benefit.

Limitations & cautions

Abstract-only summary. The trial included 630 participants, 78.1% were men, the primary confidence interval included benefit and no benefit, and individual secondary outcomes were not the primary endpoint.
AI-summarized from the linked source. Review the original article before applying to practice.

Citations · exact source links

European heart journal (PubMed). Targeted vitamin D supplementation and major adverse cardiovascular events after myocardial infarction: the TARGET-D trial.

Open original sourceFull brief

AI-summarized from the linked source. Review the original article before applying to practice.

Journal of the American Medical Directors Association (PubMed)Sep 5, 2026Research Article

A prospective Dutch nursing-home cohort found clinically important differences in illness burden across respiratory viruses, with influenza and human metapneumovirus standing out.

Geriatrics Med-SurgAI summaryReview source

Research ArticleResearchInfection ControlAI summary · original source linked below

Among 3,195 residents at 15 nursing homes, 526 suspected acute respiratory-infection episodes were recorded and a virus was identified in 291. Influenza A was associated with delayed recovery, oxygen use, and threefold secondary-bacterial-pneumonia risk; hMPV was linked to fourfold more time in bed.

Key takeaways

SARS-CoV-2, influenza A, rhinovirus or enterovirus, and RSV were the most frequently identified viruses.
hMPV and RSV tended to have higher odds of moderate or severe disease.
Virus-specific patterns were associations from a cohort, not randomized comparisons.

Why this matters on shift

Frailty can amplify respiratory-infection consequences, and the causative virus may help anticipate recovery, oxygen, mobility, and secondary-infection needs.

Bedside takeaway

Trend oxygen needs, mobility, recovery, and secondary-pneumonia signs during nursing-home respiratory infections.

Nursing implications

During outbreaks or suspected infection, trend oxygen needs, mobility and time in bed, recovery, and signs of bacterial pneumonia according to facility protocols.

Limitations & cautions

Abstract-only summary. Data came from 15 Dutch nursing homes, the overall suspected-infection risk estimate was imprecise, and virus-outcome comparisons may be affected by confounding and small subgroup counts.
AI-summarized from the linked source. Review the original article before applying to practice.

Citations · exact source links

Journal of the American Medical Directors Association (PubMed). Clinical Impact of Acute Respiratory Virus Infections in Nursing Home Residents.

Open original sourceFull brief

AI-summarized from the linked source. Review the original article before applying to practice.

How This Applies in Practice

Key takeaways

Practice implications

Limitations & cautions

Exact source links

More updates for this clinical area

One in four laboratory-defined AKI cases went undocumented on medicine wards

Targeted vitamin D did not significantly reduce major cardiovascular events after MI

Influenza and hMPV carried substantial illness burden in nursing home residents